Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

infant formula

  • Home
  •  
  • infant formula



  • Most Read
  • Latest Comments
  • Strong China growth strategy pushes A2 Milk’s revenue to double digits
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Strong China growth strategy pushes A2 Milk’s revenue to double digits
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Strong China growth strategy pushes A2 Milk’s revenue to double digits
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Strong China growth strategy pushes A2 Milk’s revenue to double digits
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Strong China growth strategy pushes A2 Milk’s revenue to double digits
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

  • Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits
    Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits
    • News

  • Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    • News

  • Investing basics: Be an empowered and informed shareholder by understanding your rights
    Investing basics: Be an empowered and informed shareholder by understanding your rights
    • Explainers

  • Synlait receives permit renewal to supply baby formula to the Chinese market
    Synlait receives permit renewal to supply baby formula to the Chinese market
    • News

  • Strong China growth strategy pushes A2 Milk’s revenue to double digits
    • News

    Strong China growth strategy pushes A2 Milk’s revenue to double digits

    Nutritional dairy company A2 Milk (ASX: A2M) might not have qualified to provide baby milk formula in the US, but it definitely succeeded on other fronts, ushering in a double-digit revenue increase of 19.8% to $1,446.2 million with the second half of FY22 up 18.9% on the first half, largely thanks to China.  The Company’s

    Read More
    Public
  • FDA deferral the latest of woes for A2 Milk as class action pasteurises
    • News

    FDA deferral the latest of woes for A2 Milk as class action pasteurises

    The FDA has deferred further consideration of one of Australia’s top dairy producers A2 Milk’s (ASX: A2M) request to import infant milk formula (IMF) into the United States. Though the application has not been rejected, it is also not close to being approved. Since February 2022, the US has been facing an acute shortage of

    Read More
    Public
  • The shut down of one major plant caused the US baby formula crisis. Aussie companies are stepping in to help.
    • News

    The shut down of one major plant caused the US baby formula crisis. Aussie companies are stepping in to help.

    I’m convinced the commodities index should include companies that manufacture toilet rolls and now, baby formula. Seemingly rarer than hen’s teeth, the powder gold is causing major headaches for parents across the US. The limited supply isn’t solely due to COVID related logistics issues, but rather the result of a sluggish government response and wider

    Read More
    Public
  • Bubs to the rescue as special operation gets underway
    • News

    Bubs to the rescue as special operation gets underway

    Shareholders of Bubs Australia (ASX: BUB) reveled in every small cap investors’ dream over the weekend – a direct shoutout from the President of the United States. And this morning the President issued a follow-up that will renew shareholders’ excitement – it might not quite get the attention of an incendiary ex President Trump tweet,

    Read More
    Public
  • Bubs launches new protein formula to meet demand from Chinese millennial mothers
    • News

    Bubs launches new protein formula to meet demand from Chinese millennial mothers

    As is becoming the case across the consumer products industry, millenials are wielding unprecedented power through irrational spending and influencer marketing. So it comes as no surprise that infant formula manufacturer Bubs (ASX: BUB) has launched a new natural A2 beta-casein protein product to quench their demand.  The new product is an extension of Bubs’

    Read More
    Public
  • Bubs executes $12 million turnaround with diversification strategy
    • News

    Bubs executes $12 million turnaround with diversification strategy

    Remember when busloads of Chinese tourists would rock up at your local supermarket and clear out the shelves of baby formulae which they then sent back to China and sold at a premium? It turns out those guys were pretty important to Australia’s milk powder industry which tanked when international border restrictions stopped them from

    Read More
    Public
  • 1
  • 2
  • 3

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.